Exicure, Inc. Announces 1-for-5 Reverse Stock Split
Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting
Exicure, Inc. Reports Second Quarter 2024 Financial Results
Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics
Exicure, Inc. Reports First Quarter 2024 Financial Results
Exicure, Inc. Reports Full Year 2023 Financial Results
Exicure, Inc. Reports Full Year 2023 Financial Results
Exicure, Inc. Reports Third Quarter 2023 Financial Results
Exicure and Bluejay Therapeutics Inc. Enter into a Patent License Agreement
Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors